Protalix BioTherapeutics, Inc. (PLX)

NYSEAMERICAN: PLX · Real-Time Price · USD
1.810
+0.070 (4.02%)
At close: Sep 12, 2025, 4:00 PM EDT
1.870
+0.060 (3.31%)
Pre-market: Sep 15, 2025, 8:51 AM EDT
4.02%
Market Cap144.32M
Revenue (ttm)61.95M
Net Income (ttm)6.28M
Shares Out 79.73M
EPS (ttm)0.08
PE Ratio23.37
Forward PE7.70
Dividendn/a
Ex-Dividend Daten/a
Volume910,941
Open1.760
Previous Close1.740
Day's Range1.730 - 1.845
52-Week Range0.990 - 3.100
Beta-0.23
AnalystsStrong Buy
Price Target15.00 (+728.73%)
Earnings DateNov 13, 2025

About PLX

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell e... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 15, 1998
Employees 213
Stock Exchange NYSEAMERICAN
Ticker Symbol PLX
Full Company Profile

Financial Performance

In 2024, Protalix BioTherapeutics's revenue was $53.40 million, a decrease of -18.47% compared to the previous year's $65.49 million. Earnings were $2.93 million, a decrease of -64.73%.

Financial Statements

Analyst Summary

According to one analyst, the rating for PLX stock is "Strong Buy" and the 12-month stock price target is $15.0.

Price Target
$15.0
(728.73% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Protalix BioTherapeutics to Present at Investor Summit Virtual

CARMIEL, ISRAEL / ACCESS Newswire / September 11, 2025 / Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of...

3 days ago - Accesswire

Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

CARMIEL, Israel, Sept. 2, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombina...

13 days ago - PRNewsWire

Protalix: Speculative Buy On Promising Plant-Cell Platform And Elfabrio Ramp

Protalix BioTherapeutics uses a plant-cell approach with ProCellEx. This has given it two approved ERTs plus PRX-115 and PRX-119. Its main focus is on a growing rare-disease pipeline. The main value d...

21 days ago - Seeking Alpha

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q2 2025 Earnings Call August 14, 2025 8:30 AM ET Company Participants Dror Bashan - President, CEO & Director Eyal Rubin - Senior VP, CFO, Treasurer & Corpor...

4 weeks ago - Seeking Alpha

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , Aug. 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focu...

4 weeks ago - PRNewsWire

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , Aug. 7, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on ...

5 weeks ago - PRNewsWire

Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

CARMIEL, Israel , July 21, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...

2 months ago - PRNewsWire

Protalix BioTherapeutics Added to Russell 3000® and 2000 Indexes®

CARMIEL, Israel , June 30, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...

2 months ago - PRNewsWire

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

CARMIEL, Israel , May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombin...

4 months ago - PRNewsWire

Protalix BioTherapeutics, Inc. (PLX) Q1 2025 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q1 2025 Earnings Conference Call May 9, 2025 8:30 AM ET Company Participants Mike Moyer – Investor Relations Dror Bashan – President and Chief Executive Offi...

4 months ago - Seeking Alpha

Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focuse...

4 months ago - PRNewsWire

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on t...

4 months ago - PRNewsWire

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline

Protalix BioTherapeutics is rated a Strong Buy due to stable income, profitability, and potential from pipeline programs PRX-115 and PRX-119. Elelyso and Elfabrio provide recurring revenue, with incre...

5 months ago - Seeking Alpha

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

CARMIEL, Israel , March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recomb...

6 months ago - PRNewsWire

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

On Monday, Protalix BioTherapeutics, Inc. PLX reported fiscal 2024 earnings of 4 cents, beating the consensus of 1 cent.

6 months ago - Benzinga

Protalix BioTherapeutics, Inc. (PLX) Q4 2024 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and...

6 months ago - Seeking Alpha

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel , March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company foc...

6 months ago - PRNewsWire

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel , March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused o...

6 months ago - PRNewsWire

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical c...

7 months ago - PRNewsWire

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

CARMIEL, Israel , Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombi...

9 months ago - PRNewsWire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Application to label a less frequent dosing regimen at a dose of 2 mg/kg body weight administered every four weeks in adult patients with Fabry disease in European Union PARMA, Italy and CARMIEL Israe...

10 months ago - PRNewsWire

Protalix BioTherapeutics, Inc. (PLX) Q3 2024 Earnings Call Transcript

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - Pr...

10 months ago - Seeking Alpha

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel , Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focu...

10 months ago - PRNewsWire

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Company to host conference call and webcast at 8:30 a.m. EST CARMIEL, Israel , Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on ...

11 months ago - PRNewsWire

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

CARMIEL, Israel , Oct. 25, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombin...

11 months ago - PRNewsWire